Octave Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 83

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $10M

  • Investors
  • 17

Octave General Information

Description

Developer of a clinical platform designed to generate, analyze, and combine data to create a new paradigm of multiple sclerosis care and other neurodegenerative diseases. The company's platform offers an integrated and multi-dimensional approach to reducing the total cost of care by optimizing healthcare medications and utilization, enabling the pharma industry to optimize the entire lifecycle of drug discovery, clinical trials, and post-marketing with real-world evidence.

Contact Information

Website
www.octavebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1440 O'Brien Drive
  • Suite B
  • Menlo Park, CA 94025
  • United States
+1 (650)
Primary Industry
Decision/Risk Analysis
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 1440 O'Brien Drive
  • Suite B
  • Menlo Park, CA 94025
  • United States
+1 (650)

Octave Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Octave Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 15-Nov-2023 $10M Completed Generating Revenue
4. Later Stage VC (Series B) 26-Jul-2023 Completed Generating Revenue
3. Grant 23-Mar-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 12-Jul-2018 $14M $16.5M Completed Generating Revenue
1. Seed Round 13-Sep-2017 $2.5M $2.5M Completed Generating Revenue
To view Octave’s complete valuation and funding history, request access »

Octave Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Seed 2,500,000 $0.000100 8% $1 $1 1x $1 8.31%
To view Octave’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Octave Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical platform designed to generate, analyze, and combine data to create a new paradigm of multiple sc
Decision/Risk Analysis
Menlo Park, CA
83 As of 2025

Philadelphia, PA
 

Morrisville, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Octave Competitors (46)

One of Octave’s 46 competitors is Proscia, a Venture Capital-Backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Proscia Venture Capital-Backed Philadelphia, PA
NantHealth Formerly VC-backed Morrisville, NC
InsightRx Venture Capital-Backed San Francisco, CA
Memotext Accelerator/Incubator Backed Bethesda, MD
Lightbeam Health Solutions Venture Capital-Backed Dallas, TX
You’re viewing 5 of 46 competitors. Get the full list »

Octave Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Octave Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021336985-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020
US-20230266342-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020
CA-3189918-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020
EP-4208869-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020
AU-2021336985-A9 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020 G01N33/6896
To view Octave’s complete patent history, request access »

Octave Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Octave Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Michael J. Fox Foundation Limited Partner
Byers Capital Family Office Minority
Casdin Capital Venture Capital Minority
Deerfield Management Venture Capital Minority
dRx Capital Novartis Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Octave FAQs

  • When was Octave founded?

    Octave was founded in 2014.

  • Where is Octave headquartered?

    Octave is headquartered in Menlo Park, CA.

  • What is the size of Octave?

    Octave has 83 total employees.

  • What industry is Octave in?

    Octave’s primary industry is Decision/Risk Analysis.

  • Is Octave a private or public company?

    Octave is a Private company.

  • What is Octave’s current revenue?

    The current revenue for Octave is .

  • How much funding has Octave raised over time?

    Octave has raised $78.5M.

  • Who are Octave’s investors?

    Michael J. Fox Foundation, Byers Capital, Casdin Capital, Deerfield Management, and dRx Capital Novartis are 5 of 17 investors who have invested in Octave.

  • Who are Octave’s competitors?

    Proscia, NantHealth, InsightRx, Memotext, and Lightbeam Health Solutions are some of the 46 competitors of Octave.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »